Search

Results for “levothyroxine”

Drug facts and side effects, recalls, research, clinical trials and medical reference, from the FDA, the National Library of Medicine and this site.

Drug lookup

Levothyroxine Sodium

Label from Lupin Pharmaceuticals, Inc.

  • Not on the FDA shortage list
  • 17 recalls in the last 3 years

Boxed warning

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.

What it is used for

Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

How it comes

Levothyroxine sodium tablets USP are round, colored, scored and debossed with following debossing details on one side and break-line on other side. They are available as follows (Table 4) Table 4: Levothyroxine Sodium Tablet Strengths and Identifying Features Tablet Strength Tablet Color/Shape...

Recalls in the last 3 years

  • Sept. 23, 2026

    Drug recall, ongoing

    Thyroid

    Vitruvias Therapeutics, sold nationwide

    Why: Superpotent Drug

    Class I: could cause serious harm or death

    About 1.2 million people in the US are prescribed thyroid each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Sept. 2, 2026

    Drug recall, ongoing

    Levothyroxine Sodium (12 products)

    Accord Healthcare, sold nationwide

    Why: Subpotent Drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • July 29, 2026

    Drug recall, ongoing

    Levothyroxine Sodium (12 products)

    Major Pharmaceuticals, sold nationwide

    Why: Subpotent Drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • July 8, 2026

    Drug recall, ongoing

    Levothyroxine Sodium

    Accord Healthcare, sold nationwide

    Why: Subpotent Drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • April 1, 2026

    Drug recall, ongoing

    Levothyroxine Sodium

    Macleods Pharma USA, sold nationwide

    Why: Subpotent Drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Jan. 21, 2026

    Drug recall, ongoing

    Levothyroxine Sodium Tablets

    Alvogen, sold nationwide

    Why: Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Oct. 15, 2025

    Drug recall, ongoing

    Levothyroxine Sodium

    Accord Healthcare, sold nationwide

    Why: Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Aug. 20, 2025

    Drug recall, ongoing

    Levothyroxine Sodium

    Pfizer

    Why: Subpotent drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • July 23, 2025

    Drug recall, ongoing

    Levothyroxine Sodium (7 products)

    Accord Healthcare, sold nationwide

    Why: Subpotent Drug: Assay below the approved specification

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • June 18, 2025

    Drug recall, ongoing

    Levothyroxine Sodium

    Macleods Pharmaceuticals, sold nationwide

    Why: Presence of a foreign substance: black hair found embedded in tablet.

    Class III: unlikely to cause harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • May 7, 2025

    Drug recall, ongoing

    Levothyroxine Sodium (4 products)

    Accord Healthcare, sold nationwide

    Why: Subpotent

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • March 26, 2025

    Drug recall, ongoing

    Levothyroxine Sodium (2 products)

    Mylan Institutional, sold nationwide

    Why: Super-Potent Drug: Out of specification potency results were obtained.

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Jan. 8, 2025

    Drug recall, terminated

    Levothyroxine Sodium

    Lupin Pharmaceuticals

    Why: Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Dec. 18, 2024

    Drug recall, ongoing

    Levothyroxine Sodium (6 products)

    Mylan Institutional, sold nationwide

    Why: Subpotent and Superpotent Drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Dec. 18, 2024

    Drug recall, ongoing

    Levothyroxine Sodium (11 products)

    Viatris, sold nationwide

    Why: Superpotent Drug and Subpotent Drug: potency failures obtained

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Dec. 11, 2024

    Drug recall, terminated

    Levothyroxine Sodium

    Accord Healthcare, sold nationwide

    Why: Subpotent drug

    Class II: could cause temporary or reversible harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)
  • Nov. 15, 2023

    Drug recall, ongoing

    Levothyroxine Sodium

    Abbvie

    Why: Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

    Class III: unlikely to cause harm

    About 19 million people in the US are prescribed levothyroxine each year.

    The FDA record, with lot numbers (opens in a new tab)

From the FDA drug label and openFDA records. For reference, not medical advice.

Most-reported side effects

312,565 reports to the FDA

  1. Fatigue26,588
  2. Nausea22,608
  3. Drug ineffective21,089
  4. Headache19,408
  5. Diarrhoea18,758
  6. Dyspnoea16,725
  7. Pain16,380
  8. Dizziness15,852
  9. Asthenia13,506
  10. Off label use13,489

From the FDA Adverse Event Reporting System. These are voluntary reports: they do not show that the drug caused the event, or how often it happens.

Research

58,866 articles in PubMed, most relevant first

  1. Trial2021 · Expert opinion on drug metabolism & toxicology

    Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial (opens in a new tab)

    Hauge C, Breitschaft A, Hartoft-Nielsen ML, et al.

  2. Review2020 · Frontiers in endocrinologyFree full text

    Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease (opens in a new tab)

    Sue LY, Leung AM

  3. 2022 · Endocrine reviewsFree full text

    Optimal Thyroid Hormone Replacement (opens in a new tab)

    Jonklaas J

  4. Review2019 · Advances in therapyFree full text

    Hypothyroidism in Context: Where We've Been and Where We're Going (opens in a new tab)

    Chiovato L, Magri F, Carlé A

  5. Guideline2025 · European thyroid journalFree full text

    ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (opens in a new tab)

    Centanni M, Duntas L, Feldt-Rasmussen U, et al.

  6. Review2025 · Medicina

    Challenges in the treatment of hypothyroidism: malabsorption and pseudo-malabsorption of levothyroxine (opens in a new tab)

    Mana DL, Rizzo LFL

See all 58,866 on PubMed (opens in a new tab)

Clinical trials

757 studies on ClinicalTrials.gov

  1. CompletedPhase 2 · started 2018

    The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis (opens in a new tab)

    Aljazeera Hospital

  2. Not yet recruitingstarted 2025

    Comparing the Therapeutic Efficacy of Extended Isthmusectomy Versus Total Thyroidectomy for Isthmus Tumors of the Thyroid (opens in a new tab)

    Second Affiliated Hospital, Zhejiang University, School of Medicine

  3. Not yet recruitingEARLY_PHASE1 · started 2025

    A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia (opens in a new tab)

    Peking University

  4. Status unknownstarted 2023

    Growth Hormone Study in Adults With Prader-Willi Syndrome (opens in a new tab)

    Erasmus Medical Center

  5. CompletedPhase 2 · started 2020

    Energy Metabolism in Thyroidectomized Patients (opens in a new tab)

    Virginia Commonwealth University

  6. Not yet recruitingstarted 2026

    Subclinical Hypothyroidism and Disease Activity in Rheumatoid Arthritis (opens in a new tab)

    Assiut University

See all 757 on ClinicalTrials.gov (opens in a new tab)

Medical reference

StatPearls, for clinicians

  1. Thyroid Disease and Pregnancy (opens in a new tab)

  2. Levothyroxine (opens in a new tab)

  3. Physiology, Thyroid Hormone (opens in a new tab)

  4. Subclinical Hypothyroidism (opens in a new tab)

See all 313 StatPearls chapters (opens in a new tab)

MedlinePlus, for patients

  1. Thyroid Diseases (opens in a new tab)

    Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your...

  2. Hyperthyroidism (opens in a new tab)

    What is hyperthyroidism? Hyperthyroidism, or overactive thyroid, happens when your thyroid gland makes more thyroid hormones than your body needs. Your thyroid is a small, butterfly-shaped gland in the front of your...

  3. Hypothyroidism (opens in a new tab)

    What is hypothyroidism? Hypothyroidism, or underactive thyroid, happens when your thyroid gland doesn't make enough thyroid hormones to meet your body's needs. Your thyroid is a small, butterfly-shaped gland in the front...

Research, trials and reference come from the National Library of Medicine (PubMed, ClinicalTrials.gov, StatPearls on the NCBI Bookshelf, MedlinePlus); drug facts, side-effect reports and recalls from the FDA. For reference, not medical advice.